Molecular Formula | C26H37NO3 |
Molar Mass | 411.58 |
Density | 1.043 |
Storage Condition | 2-8℃ |
In vitro study | Fesoterodine decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition. After oral administration, Fesoterodine is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.43 ml | 12.148 ml | 24.297 ml |
5 mM | 0.486 ml | 2.43 ml | 4.859 ml |
10 mM | 0.243 ml | 1.215 ml | 2.43 ml |
5 mM | 0.049 ml | 0.243 ml | 0.486 ml |
overview | frostidine (fesoterodine, trade name ToviazTM) is a new type of m receptor blocker, which is rapidly metabolized into active metabolites in the body and plays a role. |
use | Frostine was approved by FDA on October 31, 2008 for the treatment of overactive bladder (overactivebladder,OAB). |
Biological activity | Fesoterodine is an orally effective, non-subtype selective, competitive muscarinic receptor (mAChR) antagonist. The pKi values for M1,M2,M3,M4,M5 receptors are 8.0,7.7,7.4,7.3,7.5, respectively. Fesoterodine for overactive bladder (OAB). |
target | pKi: 8.0 (M1), 7.7 (M2), 7.4 (M3), 7.3 (M4) and 7.5 (M5) |
Animal Model: | Bladders from female Sprague-Dawley rats (225-275 g) |
Dosage: | 0.01, 0.1 and 1 mg/kg |
Administration: | IV |
Result: | Reduced the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg. |